Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of methods for achieving stable INR in healthy subjects during a multiple-dose warfarin study.

European journal of clinical pharmacology - 1 Mar 2012

Chappell Jill C, Dickinson Gemma, Mitchell Malcolm I, Haber Harry, Jin Yan, Lobo Evelyn D

Abstract excerpt

PURPOSE: No consistent method is available for finding stable warfarin maintenance doses and fast stabilization of international normalized ratio (INR) values among healthy subjects in experimental warfarin interaction studies. Using data from an earlier study that targeted a stable INR of 1.5-2....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to International Normalized Ratio
Share to Anticoagulants
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Computer Simulation

Share to Cytochrome P-450 CYP2C9

Share to Mixed Function Oxygenases

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Identifiers

PMID: 21881887
DOI: 10.1007/s00228-011-1114-4

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-21881887-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of methods for achieving stable INR in healthy subjects during a multiple-dose warfarin study.PMID 21881887Read ↗

Warfarin Pharmacogenetic Trials: Is there a Future for Pharmacogenetic-Guided Dosing?Semantic proximity Read ↗

A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age.Semantic proximity Read ↗

Estimation of the warfarin dose with clinical and pharmacogenetic data.Semantic proximity Read ↗

Current challenges in personalizing warfarin therapy.Semantic proximity Read ↗

Time-to-event modeling for achieving a stable warfarin dose using genetic and non-genetic covariates.Semantic proximity Read ↗

A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy.Semantic proximity Read ↗

S-warfarin limited sampling strategy with a population pharmacokinetic approach to estimate exposure and cytochrome P450 (CYP) 2C9 activity in healthy adults.Semantic proximity Read ↗

Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin.Semantic proximity Read ↗

Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy.Semantic proximity Read ↗

Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation.Semantic proximity Read ↗

Personalized Anticoagulation: Optimizing Warfarin Management Using Genetics and Simulated Clinical Trials.Semantic proximity Read ↗

S-Warfarin Limited Sampling Models to Estimate Area Under the Concentration Versus Time Curve for Cytochrome P450 2C9 Baseline Activity and After Induction.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.